AbbVie tacks on OSE Immunotherapeutics asset to inflammation pipeline

28 Feb 2024
firstwordpharma.com
License out/inImmunotherapy
AbbVie will gain an exclusive global licence to further develop a monoclonal antibody from OSE Immunotherapeutics designed to resolve chronic and severe inflammation. The deal, announced Tuesday, includes an upfront payment of $48 million and is potentially worth over $700 million to OSE.
"By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism-of-action to treat chronic inflammation,” remarked Jonathon Sedgwick, global head of discovery research at AbbVie.
OSE-230 is designed to activate the GPCR target ChemR23, modulating functions of both macrophages and neutrophils. The compound is currently in preclinical development.
In addition to the upfront sum, OSE is eligible to receive up to $665 million in milestone payments, as well as tiered sales royalties if OSE-230 reaches the market.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.